ONCY Oncolytics Biotech, Inc.: Enterprise Value-to-Revenue Multiple

Oncolytics (ONCY) - corporate logo

Oncolytics Biotech Inc. (ONCY) is developing viral platforms through partnerships with industry behemoths to accelerate therapy testing. The EV/Sales ratio on the GURU.Markets daily chart reflects valuation dynamics, where the value 0.00 captures the metric level. Oncolytics Biotech Inc. (ONCY) is implementing energy-saving technologies in biomanufacturing and scaling breast cancer treatment for FDA registration.

Oncolytics Biotech - ONCY Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

ONCY (Oncolytics): analytical breakdowns and indicator data

- stock quotes and analyst forecast:
Initial company analysis:Oncolytics Biotech, Inc., ONCY
Original product of Oncolytics Biotech, Inc.

Accurate business valuation is critical for identifying fundamental sector leaders. This indicator compares the total enterprise value with annual revenue, neutralizing the impact of debt load. For Oncolytics Biotech Inc. (ONCY), this metric reflects market demand for innovation amid a reliance on external contract laboratories. Effective management of medical protocols directly impacts investment attractiveness. By analyzing the EV/Sales ratio trend, an investor determines the degree to which the asset is overbought.